> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bioventus Posts $47.0 Million Nine-Month Profit On A Tax Benefit Bigger Than Its Pretax Income
- URL: https://www.bullished.co/bioventus-posts-47-0-million-nine-month-profit-on-a-tax-benefit-bigger-than-its-pretax-ff44c6cf/
- Published: 2026-11-02T22:21:44.000Z
- Updated: 2026-11-02T22:21:44.000Z
- Description: A noncash tax release lifted nine-month net income while third-quarter operating income fell to $9.7 million from $11.3 million.
- Author: Matteo Parrino
- Tags: Earnings, BVS, Industry: Healthcare

[Bioventus](https://www.bullished.co/tag/bvs/), which makes pain, surgical and bone-healing medical devices, earned [$47.0 million](https://www.sec.gov/Archives/edgar/data/0001665988/000166598826000052/bvs-20260926.htm?ref=bullished.co) over the first nine months of 2026, but a $21.0 million income tax benefit did much of the work: pretax income was only $26.0 million. Third-quarter operating income, meanwhile, fell to $9.7 million from $11.3 million a year earlier, the company said in its 10-Q filed Monday.

## A tax line that outran pretax profit

For the nine months, the company booked a $21.0 million tax benefit against $1.6 million of tax expense a year earlier. Behind it sit $26.9 million of valuation allowance releases, which are accounting reversals of earlier write-downs on deferred tax assets. The 10-Q says the benefit is noncash and did not add to operating cash inflows.

The [second-quarter filing](https://www.sec.gov/Archives/edgar/data/0001665988/000166598826000042/bvs-20260627.htm?ref=bullished.co) carried $24.6 million of that release, and the third quarter added $2.3 million. The remaining allowance is about $20.7 million, and $18.6 million of it relates mainly to capital loss carryforwards and foreign tax credits whose realization remains uncertain. The company said the third-quarter release reflects management's change in judgment.

The company's adjusted earnings measure strips the release out. The company's [earnings release](https://www.sec.gov/Archives/edgar/data/0001665988/000166598826000050/bioventusex-991q32026.htm?ref=bullished.co) put third-quarter adjusted earnings at $0.17 per diluted share, against $0.15 a year earlier.

## Operating income slips as costs climb

Third-quarter pretax income rose to $6.2 million from $4.7 million, helped by lower interest expense. Operating income went the other way. Selling, general and administrative expense rose 5.5% to $82.9 million, with $2.3 million more in professional services, including legal costs partly tied to the strategic review, and $1.4 million more in consulting tied mainly to it.

[Revenue rose 2.7%](https://seekingalpha.com/news/4662965-bioventus-non-gaap-eps-of-0%5F17-beats-by-0%5F01-revenue-of-142%5F4m-misses-by-7%5F12m?ref=bullished.co) to $142.4 million, led by Pain Treatments. Surgical Solutions and Restorative Therapies fell in the U.S.

Bioventus makes hyaluronic acid knee injections, nerve stimulation devices, ultrasonic bone-cutting systems and the EXOGEN fracture-healing device. The U.S. is 88% of sales, as of the fiscal year ended December 31, 2025.

## Debt paydown and the strategic review

The company has prepaid its 2025 term loan by $22.0 million, $20.0 million and $15.0 million in the first three quarters of 2026\. Its market value was $910 million in Monday trading.

The quarter brought a $3.6 million addback for strategic alternatives costs, a line that did not exist a year earlier. An unsolicited acquisition proposal prompted the review. The 10-Q no longer carries it as a separate discussion section or risk factor, though the earnings release says the company continues to review alternatives.

CEO Rob Claypoole said the company would "continue to review potential [strategic alternatives](https://www.globenewswire.com/news-release/2026/11/02/3393722/0/en/bioventus-reports-third-quarter-financial-results.html?ref=bullished.co) for the Company as we explore all opportunities to maximize value for our shareholders."

The company updated 2026 net sales guidance to $590 million to $595 million, and its fourth-quarter report will show whether operating income recovers.

### Sources

- [10-Q Filing — Bioventus (BVS)](https://www.sec.gov/Archives/edgar/data/0001665988/000166598826000052/bvs-20260926.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Bioventus (BVS), Q2 FY2026 filed 2026-08-05 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001665988/000166598826000042/bvs-20260627.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, bioventusex-991q32026.htm) — Bioventus, filed 2026-11-02](https://www.sec.gov/Archives/edgar/data/0001665988/000166598826000050/bioventusex-991q32026.htm?ref=bullished.co) — SEC EDGAR
- [Bioventus Non-GAAP EPS of $0.17 beats by $0.01, revenue of $142.4M misses by $7.12M (BVS:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4662965-bioventus-non-gaap-eps-of-0%5F17-beats-by-0%5F01-revenue-of-142%5F4m-misses-by-7%5F12m?ref=bullished.co) — seekingalpha.com
- [Bioventus LLC : Articles :: Law360](https://www.law360.com/companies/bioventus-llc?ref=bullished.co) — law360.com
- [Bioventus Reports Third Quarter Financial Results](https://www.globenewswire.com/news-release/2026/11/02/3393722/0/en/bioventus-reports-third-quarter-financial-results.html?ref=bullished.co) — globenewswire.com

### More on Bioventus

- [Bioventus Cuts Interest Bill By Nearly Half In Quarter, Lifting Adjusted EPS 13% While Sale Review Continues](https://www.bullished.co/bioventus-cuts-interest-bill-by-nearly-half-in-quarter-lifting-adjusted-eps-13-while-sale-3d4a1f4a/)

[All Bioventus (BVS) coverage →](https://www.bullished.co/tag/bvs/)